Excipient Enhanced Growth Aerosol Surfactant Replacement Therapy in an In Vivo Rat Lung Injury Model
Background: In neonatal respiratory distress syndrome, breathing support and surfactant therapy are commonly used to enable the alveoli to expand. Surfactants are typically delivered through liquid instillation. However, liquid instillation does not specifically target the small airways. We have developed an excipient enhanced growth (EEG) powder aerosol formulation using Survanta®. Methods: EEG Survanta powder aerosol was delivered using a novel dry powder inhaler via tracheal insufflation to surfactant depleted rats at nominal doses of 3, 5, 10, and 20 mg of powder containing 0.61, 0.97, 1.73, and 3.46 mg of phospholipids (PL), whereas liquid Survanta was delivered via syringe instillation at doses of 2 and 4 mL/kg containing 18.6 and 34 mg of PL. Ventilation mechanics were measured before and after depletion, and after treatment. We hypothesized that EEG Survanta powder aerosol would improve lung mechanics compared with instilled liquid Survanta in surfactant depleted rats. Results and Conclusion: EEG Survanta powder aerosol at a dose of 0.61 mg PL significantly improved lung compliance and elastance compared with the liquid Survanta at a dose of 18.6 mg, which represents improved primary efficacy of the aerosol at a 30-fold lower dose of PL. There was no significant difference in white blood cell count of the lavage from the EEG Survanta group compared with liquid Survanta. These results provide an in vivo proof-of-concept for EEG Survanta powder aerosol as a promising method of surfactant replacement therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Journal of aerosol medicine and pulmonary drug delivery - 33(2020), 6 vom: 06. Dez., Seite 314-322 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kamga Gninzeko, Franck J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.10.2021 Date Revised 03.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/jamp.2020.1593 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310356776 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310356776 | ||
| 003 | DE-627 | ||
| 005 | 20231225135922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/jamp.2020.1593 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1034.xml |
| 035 | |a (DE-627)NLM310356776 | ||
| 035 | |a (NLM)32453638 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kamga Gninzeko, Franck J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Excipient Enhanced Growth Aerosol Surfactant Replacement Therapy in an In Vivo Rat Lung Injury Model |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.10.2021 | ||
| 500 | |a Date Revised 03.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: In neonatal respiratory distress syndrome, breathing support and surfactant therapy are commonly used to enable the alveoli to expand. Surfactants are typically delivered through liquid instillation. However, liquid instillation does not specifically target the small airways. We have developed an excipient enhanced growth (EEG) powder aerosol formulation using Survanta®. Methods: EEG Survanta powder aerosol was delivered using a novel dry powder inhaler via tracheal insufflation to surfactant depleted rats at nominal doses of 3, 5, 10, and 20 mg of powder containing 0.61, 0.97, 1.73, and 3.46 mg of phospholipids (PL), whereas liquid Survanta was delivered via syringe instillation at doses of 2 and 4 mL/kg containing 18.6 and 34 mg of PL. Ventilation mechanics were measured before and after depletion, and after treatment. We hypothesized that EEG Survanta powder aerosol would improve lung mechanics compared with instilled liquid Survanta in surfactant depleted rats. Results and Conclusion: EEG Survanta powder aerosol at a dose of 0.61 mg PL significantly improved lung compliance and elastance compared with the liquid Survanta at a dose of 18.6 mg, which represents improved primary efficacy of the aerosol at a 30-fold lower dose of PL. There was no significant difference in white blood cell count of the lavage from the EEG Survanta group compared with liquid Survanta. These results provide an in vivo proof-of-concept for EEG Survanta powder aerosol as a promising method of surfactant replacement therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a EEG Survanta powder aerosol | |
| 650 | 4 | |a compliance | |
| 650 | 4 | |a elastance | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a resistance | |
| 650 | 4 | |a surfactant depletion | |
| 650 | 4 | |a ventilation mechanics | |
| 650 | 7 | |a Aerosols |2 NLM | |
| 650 | 7 | |a Excipients |2 NLM | |
| 650 | 7 | |a Powders |2 NLM | |
| 650 | 7 | |a Pulmonary Surfactants |2 NLM | |
| 700 | 1 | |a Valentine, Michael S |e verfasserin |4 aut | |
| 700 | 1 | |a Tho, Cindy K |e verfasserin |4 aut | |
| 700 | 1 | |a Chindal, Sahil R |e verfasserin |4 aut | |
| 700 | 1 | |a Boc, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Dhapare, Sneha |e verfasserin |4 aut | |
| 700 | 1 | |a Momin, Mohammad Abdul Motalib |e verfasserin |4 aut | |
| 700 | 1 | |a Hassan, Amr |e verfasserin |4 aut | |
| 700 | 1 | |a Hindle, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Farkas, Dale R |e verfasserin |4 aut | |
| 700 | 1 | |a Longest, P Worth |e verfasserin |4 aut | |
| 700 | 1 | |a Heise, Rebecca L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of aerosol medicine and pulmonary drug delivery |d 2008 |g 33(2020), 6 vom: 06. Dez., Seite 314-322 |w (DE-627)NLM179940449 |x 1941-2703 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2020 |g number:6 |g day:06 |g month:12 |g pages:314-322 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/jamp.2020.1593 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2020 |e 6 |b 06 |c 12 |h 314-322 | ||